Rune Labs Unveils $12 Million Strategic Round to Accelerate Adoption of Novel Parkinson ’s Technologies

Brings Total Raised to Over $42 Million Co-Founder of Nexus NeuroTech and Former Verily President of Medical Devices Jordi Parramon Joins as New Board Member Rune Labs, a precision neurology software and data company, today announced a strategic round of $12 million, increasing the total amount raised by the company to over $42 million. The round was led by new brain disorder fund, Nexus NeuroTech Ventures, with participation from existing investors, including Eclipse, DigiTx Partners, Moment Ventures, and TruVenturo GmbH. Jordi Parramon, PhD, CEO, General Partner, and Co-Founder of Nexus NeuroTech Ventures and former President of Medical Devices at Verily, will join Rune Labs’ board of directors. “Since launching in 2021, Rune Labs’ StrivePD software has become the most widely used software by Parkinson’s patients and clinicians, and we have built complementary business lines that leverage our network and data to support both clinical development and comprehensive care management,” said Rune Labs CEO, Brian Pepin. “With over 25 years of experience, Jordi brings deep knowledge in building businesses and products and the intersection of data and healthcare. This strategic partnership with Nexus NeuroTech Ventures is in line with our use of modern AI tools to support patients, clinicians, and our pharma partners, and speaks to our ambition to have a deep impact in the way Parkinson’s is understood and treated.” In 2022, Rune Labs’ StrivePD software ecosyste...
Source: EMR and HIPAA - Category: Information Technology Authors: Tags: Health IT Company Healthcare IT Aspen Neuroscience Benjamin Stecher BlueRock Therapeutics Brian Pepin DigiTx Partners Eclipse Health IT Funding Health IT Fundings Health IT Investment Jordi Parramon Moment Ventures Nexus NeuroTec Source Type: blogs